According to Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) released its 2023 annual results report. During the reporting period, the company achieved operating income of 1,783 million yuan, a year-on-year decrease of 4.67%; net loss attributable to shareholders of listed companies of 195 million yuan, and net profit of 459.44,900 yuan in the same period last year; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 232 million yuan; basic loss per share.
尔康制药(300267.SZ)发布2023年度业绩，净亏损1.95亿元 同比盈转亏
Erkang Pharmaceutical (300267.SZ) announced its 2023 annual results, with a net loss of 195 million yuan from profit to loss
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.